Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
Universitat Autònoma de Barcelona
Abstract
Progression independent of relapse activity (PIRA) is the main event responsible for irreversible disability accumulation in relapsing multiple sclerosis (MS).
To investigate clinical and neuroimaging predictors of PIRA at the time of the first demyelinating attack and factors associated with long-term clinical outcomes of people who present with PIRA. Design, Setting, and Participants: This cohort study, conducted from January 1, 1994, to July 31, 2021, included patients with a first demyelinating attack from multiple sclerosis; patients were recruited from 1 study center in Spain. Patients were excluded if they refused to participate, had alternative diagnoses, did not meet protocol requirements, had inconsistent demographic information, or had less than 3 clinical assessments. Exposures: Exposures included (1) clinical and neuroimaging features at the first demyelinating attack and (2) presenting PIRA, ie, confirmed disability accumulation (CDA) in a free-relapse period at any time after symptom onset, within (vs after) the first 5 years of the disease (ie, early/late PIRA), and in the presence (vs absence) of new T2 lesions in the previous 2 years (ie, active/nonactive PIRA). Main Outcomes and Measures: Expanded Disability Status Scale (EDSS) yearly increase rates since the first attack and adjusted hazard ratios (HRs) for predictors of time to PIRA and time to EDSS 6.0.
Citation impact
- FWCI
- 34.45
- Percentile
- 100%
- References
- 19
Authors
21Topics & keywords
- Expanded Disability Status Scale
- Medicine
- Multiple sclerosis
- Hazard ratio
- Cohort
- Proportional hazards model
- Disease
- Internal medicine
- Good health and well-being
Funding
- NMNational Multiple Sclerosis Society
- BSBristol-Myers Squibb
- SSanofi
- BBiogen
- TPTeva Pharmaceutical Industries
- APAlexion Pharmaceuticals
- CCelgene
- FHF. Hoffmann-La Roche
- “C“la Caixa” Foundation
- TTTG Therapeutics
- MMylan
- MDMinisterio de Ciencia e InnovaciónAward: PI21/01860
- OGOryzon Genomics
- MPMedDay Pharmaceuticals
- ESEMD Serono
- SGSanofi Genzyme
- IDInstituto de Salud Carlos IIIAward: PI21/01860